Institute for Molecular Medicine Finland

The pharma company will analyze genomic and clinical data from 2 million individuals over the next 10 years to drive drug development across its entire portfolio. 

NEW YORK (GenomeWeb News) – Studies by two independent research teams published online yesterday in Nature Neuroscience suggest a single gene — the enzyme-coding gene called TOP3B — contributes to processes related to schizophrenia and to a syndrome associated with autism spectrum disord

NEW YORK (GenomeWeb News) – Labcyte said today that the Institute for Molecular Medicine Finland, known as FIMM, will use Labcyte's acoustic liquid handling technology in its small molecule-based personalized cancer medicine programs, under a new collaboration.

The company's Multiplexing Diagnostics division will use the arrayer to develop molecular tools, including protein biomarkers, to diagnose allergy and autoimmunity.

The program will consist of miniaturized RNAi screens, and in the future will include compound/drug arrays.

FIMM studies cancer, as well as cardiovascular, neuro-psychiatric and viral diseases, carries out translational research, and seeks to promote human health through research on personalized medicine.

The Nordic nation will invest in a pan-European pilot program for cultivating informatics, biobanking, and translational research.

Even when given the option, not too many authors choose double-blinded peer-review for their manuscripts, ScienceInsider reports.

The Save the Redwoods League is teaming with researchers to sequence the genomes of the coast redwood and giant sequoia.

In PNAS this week: transcriptional read-through in stressed cells, genome stability role for the epigenetic regulator CTCF, and more.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.